Registration
Registration: starting at 7:30 a.m
Program
Registration: starting at 7:30 a.m
Authorities and CEL-GEN / ABTCel-Gen leadership
Jim Wilson, Gemma Therapeutics
Tumor Infiltrating Lymphocytes
Chairs: to be defined
Tiago da Silva Medina, University of Southern Denmark
Luciana Cavalheiro Marti, Hospital Israelita Albert Einstein
Workshop window: 12:30 – 13:15
Workshop window: 12:30 – 13:15
Chairs: to be defined
Sponsored by CCT-RNA
Mariana Mello, Scripps
Jamile Ramos da Silva, Hospital Israelita Albert Einstein
Santuza Maria Ribeiro Teixeira, UFMG
Sponsored by IMASP
Chairs: Roberto Giugliani & Antonio Carlos Campos de Carvalho, HCPA / UFRJ
Jim Wilson, Gemma Therapeutics
Milena Botelho Pereira Soares, Fiocruz-BA
Iscia Lopes-Cendes, UNICAMP
Chairs: to be defined
Veronica Lopez, Fundación Instituto Leloir
Marcio Chaim Bajgelman, CNPEM
Oral Abstract 80: NEUROGENIN 2 overexpression in corticospinal neurons modulates early neuronal and microglial responses after spinal cord injury
Oral Abstract 153: AAV-mediated overexpression of cannabinoid CB1 receptors preserves functional responses in a mouse model of retinitis pigmentosa
Chairs: to be defined
Stevens Rehen, Instituto D'Or
Patricia Braga, USP
Oral Abstract 37: Bioengineering a human lung-on-a-chip platform toward immune-informed preclinical modeling of pulmonary advanced therapies
Oral Abstract 66: Development and validation of a CAPN1 knockout SH-SY5Y cell model via CRISPR-Cas9 for SPG76 studies
Chairs: to be defined
Diego Villa Clé, USP-RP
Marina Carolina de Oliveira Rodrigues, USP-RP
Lorena Lôbo de Figueiredo Pontes, USP-RP
Chairs: to be defined
Marlon Lemos Dias, UFRJ
Silvya Stuchi Maria-Engler, USP
Oral Abstract 19: Experimental evolution of Zika virus for adaptation in differentiated cells of glioblastoma to enhance oncolytic activity
Oral Abstract 24: Air-jet-generated alginate microgels enable controlled and functional release of AAV vectors for gene therapy applications
Transition Break / Room Reset
Gene Therapy - Translation and Clinical Trials
Chairs: to be defined
Jonathan Yen, St. Jude Children's Research Hospital
Leszek Lisowski, CMRI / Gene2Cure
ABTCel-Gen (ABTA) General Assembly
Chairs: to be defined
Angela Saito — CNPEM
Davi Coe Torres — Hospital Israelita Albert Einstein
Oral Abstract 107: Sustained reactivation of fetal hemoglobin by adenine base editors in human hematopoietic stem cells for sickle cell disease
Oral Abstract 28: Gene therapy with AAV9 in cellular models for glutaric acidemia type I developed via CRISPR/Cas9 gene editing
Chairs: to be defined
Lucia Silla — HCPA-UFRGS
Mariana Marques — Hospital Albert Einstein
Oral Abstract 88: Lentiviral vector platform based on packaging cell line engineering and GMP-oriented process development
Oral Abstract 76: Establishing GMP-compliant CAR-T cell manufacturing at INCA for an upcoming pediatric clinical trial in Brazil
Chairs: to be defined
Leonardo Martins — University of Antwerp
Ana Paula Dinis Ano Bom — Bio-Manguinhos
Oral Abstract 170: Optimization and preclinical validation of an mRNA-LNP vaccine candidate against Chikungunya virus
Oral Abstract 57: Scaling up the non-viral production of CD19 CAR-T cells using a minicircle-based Sleeping Beauty transposon system
Chairs: to be defined
Lara Cristina Pereira — ANVISA
Luciana Piano — ARO-Einstein — Nova Regulamentação em Pesquisa Clínica
Mônica Felts — Diretora Científica, CNPq
Workshop window: 12:45 – 13:30
Workshop window: 12:45 – 13:30
Chairs: to be defined
Sponsored by INTERGEN
Juan Fueyo — MD Anderson Cancer Center
Candelaria Gomez-Manzano — MD Anderson Cancer Center
Wagner José Fávaro — UNICAMP
Chairs: to be defined
Sponsored by CCTA-EMBRAPII
Lucia Nassif Kerbauy — Hospital Israelita Albert Einstein
Augusto Barbosa Junior — Hospital Israelita Albert Einstein
Eduardo Ferreira de Carvalho Netto — Hospital Israelita Albert Einstein
Chairs: to be defined
Thiago Aparecido Silva - UNESP-Araraquara
Rodrigo Nalio Ramos - Instituto D'Or
Oral Abstract 14: A Lentiviral EDV Platform for simultaneous CAR Engineering and CRISPR Gene Editing in Primary T and NK Cells
Oral Abstract 79: Cell therapy targeting fungal pathogens: optimization of Mannan-Specific Chimeric Antigen Receptor (M-CAR)
Chairs: to be defined
Ricardo Titze - UnB
Tatiana Martins Tilli - Fiocruz
Oral Abstract 42: Isoform-resolved lncRNA remodeling as a secondary readout of SCN2A dosage and CRISPRa-mediated activation in human iPSC-derived cortical excitatory neurons
Oral Abstract 34: From cells to patients: gene therapy with p14ARF and interferon-? reveals antitumor and immunomodulatory mechanisms in canine neoplasms
Mesenchymal Stem Cells
Chair: Tatiana Maron Gutierrez - Fiocruz
Daniel Weiss - University of Vermont
Patricia Rocco - UFRJ
IGI Session
Chair: Bruno Solano de Freitas Souza - Instituto D'Or
Ross Wilson - Innovative Genomics Institute
Fyodor Urnov - UC Berkeley
Chairs: to be defined
Fernanda Ferreira Cruz, UFRJ
Bruno Solano de Freitas Souza, Instituto D'Or
Oral Abstract 59: Investigation of the neuroprotective role of extracellular vesicles from physical exercise and associated with FNDC5/irisin in preclinical models of Alzheimer's disease
Oral Abstract 104: 3D Bioprinted Wound Dressings Containing 5-Azacytidine-Preconditioned Human Umbilical Cord Mesenchymal Stromal Cells for the Treatment of Severe Cutaneous Wounds in a Murine Model of Sickle Cell Disease
Chairs: to be defined
Hilda Petrs-Silva, UFRJ
Guilherme Baldo, UFRGS
Oral Abstract 17: Construction and evaluation of an HSV-1-based oncolytic virus expressing the pro-apoptotic protein sFTRAIL, for the treatment of head and neck tumors
Oral Abstract 146: Therapeutic DNA vaccination targeting HPV16 E5 and E7 oncoproteins: evaluation of different immunization regimens in a preclinical tumor model
Past, Present and Future of AAVs
Chairs: to be defined
To be defined
Arun Srivastava, University of Florida
Workshop window: 12:00 – 12:45
Workshop window: 12:00 – 12:45
Chairs: to be defined
Stephan Kadauke, CHOP
Juliana Dias, University College London
Oral Abstract 142: Phage display selection of scFvs specific for the HER2 S310F mutation from rationally designed libraries based on pertuzumab
Oral Abstract 6: Engineering CAR-T cells to enhance tumor infiltration in solid tumors
Chairs: to be defined
Juliana Maria Ferraz Salum, Escola Paulista de Medicina / UNIFESP
Jonas Alex Morales, UFRGS
Oral Abstract 187: Will It Reach Patients? An AI model predicts clinical translation of gene therapies from modifiable preclinical design choices
Oral Abstract 198: Safety and Preliminary Efficacy of a Brazil-Developed CMV pp65-Specific T-Cell Therapy for Clinically Significant CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Interim Results of a Phase I Study
Chairs: to be defined
Sponsored by ONCOTTGEN
André Silva Pimentel, PUCRS
Alfeu Zanotto-Filho, UFSC
Pedro Pires Goulart Guimarães, UFMG
Chairs: to be defined
Sponsored by INCT-Model3D
Marcelo Lazzaron Lamers, UFRGS
Fabio Papes, UNICAMP
Vanessa Morais Freitas, USP
Prepare your presentation using the CEL-GEN 2026 visual identity. Choose one of the templates below and download the editable PowerPoint file to customize your slides.
AVISO IMPORTANTE
Informamos que a relação dos trabalhos científicos apresentados no CEL-GEN 2026 encontra-se disponível ao final do Livro de Programação, em formato simplificado, devido a limitações técnicas do sistema eletrônico de submissão utilizado.
A Comissão Organizadora reconhece essas limitações e esclarece que as informações completas dos trabalhos, incluindo títulos e autoria, serão devidamente contempladas nos certificados de apresentação.
Para assegurar a emissão correta dos certificados, solicitamos aos autores que encaminhem o resumo completo, em formato Word (.docx), à Secretaria da ABTCel-Gen, por meio do e-mail (contato@abtcelgen.org.br).
Agradecemos a compreensão e a colaboração de todos.
Comissão Organizadora | CEL-GEN 2026
IMPORTANT NOTICE
Please be informed that the list of scientific abstracts presented at CEL-GEN 2026 is available at the end of the Program Book in a simplified format due to technical limitations of the electronic submission system.
The Organizing Committee acknowledges these limitations and wishes to clarify that complete information for each contribution, including the full title and all authors, will be accurately reflected in the corresponding presentation certificates.
To ensure the accurate issuance of these certificates, we kindly request that authors submit their complete abstracts in Word format (.docx) to the ABTCel-Gen Secretariat via email e-mail (contato@abtcelgen.org.br).
We sincerely appreciate your understanding and cooperation.
Organizing Committee | CEL-GEN 2026
Submission is closed.
Poster format:
Regulations for submitting abstracts to Cel-Gen 2026
All abstracts must be written in English, and abstracts selected for oral presentation must also be presented in English.
Submission opening and closing date/time:
Opening: June 1st
Closing: June 30, 12:00 a.m. (midnight) Postponed to August 02, 12:00 a.m. (midnight)
Maximum number of abstracts per author: 3 abstracts
Maximum number of authors per abstract: 15 authors
Title length limit: 250 characters (including spaces)
Abstract length limit: Abstracts are limited to 3,000 characters, including punctuation and spaces (excluding title, authors, and affiliations)
Authors may submit abstracts before completing registration/payment. Registration fees will only be required after abstract acceptance.
Evaluation score/rating scale: up to 6 points
Work presentation formats: Poster and Oral Presentation
Categories:
Questions: contact@abtcelgen.org.br; temalivre3@mezclaeventos.com.br